Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Galmed Pharmaceuticals Ltd. announced the grant of new use patents for combining its drug Aramchol with Madrigal Pharmaceuticals’ Rezdiffra for MASH treatment. The patent, granted in South Korea, extends Aramchol’s U.S. patent protection until July 2042, strengthening its position in combination therapies for MASH.
Galmed Pharmaceuticals Ltd. has announced the grant of new use patents for the combination of its drug candidate Aramchol with Madrigal Pharmaceuticals’ Rezdiffra (Resmetirom) for the treatment of MASH. The new patent, recently granted in South Korea, adds to earlier patents already granted in the United States, Europe, Canada, and other jurisdictions, extending Aramchol’s patent protection in the U.S. until July 2042. The company highlighted that this development strengthens its position in the emerging field of combination therapies for MASH, where Aramchol’s safety and tolerability make it an ideal candidate for use alongside other drugs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO39286) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
